The U.S. Food and Drug Administration (FDA) has issued a Safety Announcement Warning that compulsive, uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug Abilify® (aripiprazole).
Abilify® is a top-selling prescription drug prescribed to treat depression, bipolar disorder, schizophrenia and Tourette syndrome. Abilify®acts on the same nerves in the brain that are activated by dopamine, which stimulates pleasure centers in the brain. The FDA reports that these uncontrollable were reported to have stopped when the medication was discontinued or the dose was reduced.
The FDA said the label on Abilify® currently includes warnings about compulsive gambling, but that the warnings do not entirely reflect the nature of the impulse-control risk identified, and it does not adequately warn about other compulsive behaviors associated with use of the drug. The following risks will be added to the label:
- Pathological gambling
- Binge eating
- Spending or shopping excessively
According to the FDA, anyone on Abilify®could experience compulsive syndromes. The manufacturer of Abilify®, Bristol-Myers Squibb, is facing a growing number of lawsuits from people who say they were not adequately warned about the risk. In October 2014, JAMA Internal Medicine published a study in which researchers identified over 700 reports of impulse-control disorders associated with dopamine-receptor agonists. They recommended a “Black Box” warning on Abilify®.
Do I have an Abilify® Lawsuit?
Houssiere Durant Houssiere, LLP is currently accepting Abilify® induced injury cases. If you or somebody you know was diagnosed with an impulse disorder, you should contact our lawyers immediately for a free case consultation. Please use the form or call toll free 24 hours a day at (888) 881-8100.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case please contact us at 1-888-881-8100.